Table 2 Evaluation of the 7-AAb panel in AFP− HCC detection
From: Autoantibody signature in hepatocellular carcinoma using seromics
Phase | AFP− HCC vs. (healthy + cirrhotic) | AFP− HCC vs. healthy | AFP− HCC vs. cirrhotic | ||||||
|---|---|---|---|---|---|---|---|---|---|
AUC | Specificity | Sensitivity | AUC | Specificity | Sensitivity | AUC | Specificity | Sensitivity | |
Test phase (II) | 0.898 | 89.4% | 70.4% | 0.937 | 88.9% | 83.5% | 0.841 | 87.0% | 64.3% |
Validation phase (III) | 0.926 | 90.1% | 80.6% | 0.948 | 93.4% | 83.7% | 0.886 | 85.2% | 77.5% |
Test phase (II) + validation phase (III) | 0.912 | 89.1% | 76.1% | 0.942 | 93.4% | 80.3% | 0.862 | 89.6% | 65.7% |